LEGN - Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
2024-02-25 05:00:00 ET
Summary
- AlphaGen Therapeutics and ArtBio, two targeted RLT companies, forged a far-reaching agreement to expand ArtBio’s market and develop new RLTs.
- Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences, granting access to Biocytogen’s fully human antibody library aimed at a wide range of therapeutic targets.
- Legend Biotech reported Europe’s CHMP recommended approval of its lead CAR-T drug, Carvykti®, for a new indication.
Deals and Financings
Shanghai AlphaGen Therapeutics and ArtBio of Cambridge MA, two targeted radioligand therapy (RLT) companies, forged a far-reaching agreement to expand AriBio's market and develop new RLTs. AlphaGen will have China rights to use ArtBio's AlphaDirect™ isotope isolation technology to generate 212Pb, a unique isotope without a global supply. It will also have a license to develop AB001, a clinical-stage alpha RLT targeting prostate-specific membrane antigen (PSMA), in Greater China. And AlphaGen will have the right to use ArtBio's AlphaDirect™ platform to develop 212Pb RLTs against additional targets. ArtBio will have a minority equity interest in AlphaGen as part of the agreement....
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership